HomeCompareMCK vs RMD

MCK vs RMD: Dividend Comparison 2026

MCK yields 0.38% · RMD yields 1.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MCK wins by $12.5K in total portfolio value· pulled ahead in Year 7
10 years
MCK
MCK
● Live price
0.38%
Share price
$860.19
Annual div
$3.28
5Y div CAGR
66.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.3K
Annual income
$10,761.37
Full MCK calculator →
RMD
RMD
● Live price
1.06%
Share price
$220.03
Annual div
$2.33
5Y div CAGR
35.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.7K
Annual income
$3,288.25
Full RMD calculator →

Portfolio growth — MCK vs RMD

📍 MCK pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMCKRMD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MCK + RMD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MCK pays
RMD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MCK
Annual income on $10K today (after 15% tax)
$32.41/yr
After 10yr DRIP, annual income (after tax)
$9,147.16/yr
RMD
Annual income on $10K today (after 15% tax)
$90.01/yr
After 10yr DRIP, annual income (after tax)
$2,795.01/yr
At 15% tax rate, MCK beats the other by $6,352.15/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MCK + RMD for your $10,000?

MCK: 50%RMD: 50%
100% RMD50/50100% MCK
Portfolio after 10yr
$38.0K
Annual income
$7,024.80/yr
Blended yield
18.49%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MCK right now

MCK
Analyst Ratings
1
Strong
24
Buy
6
Hold
Consensus: Buy
Price Target
$982.38
+14.2% upside vs current
Range: $900.00 — $1,085.00
Altman Z
5.9
Piotroski
7/9
RMD
Analyst Ratings
16
Buy
14
Hold
5
Sell
Consensus: Buy
Price Target
$295.88
+34.5% upside vs current
Range: $265.00 — $345.00
Altman Z
11.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MCK buys
0
RMD buys
0
No recent congressional trades found for MCK or RMD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMCKRMD
Forward yield0.38%1.06%
Annual dividend / share$3.28$2.33
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR66.7%35.9%
Portfolio after 10y$44.3K$31.7K
Annual income after 10y$10,761.37$3,288.25
Total dividends collected$22.6K$10.4K
Payment frequencyquarterlyquarterly
SectorHealthcareHealthcare
Analyst consensusBuyBuy
Analyst price target$982.38$295.88

Year-by-year: MCK vs RMD ($10,000, DRIP)

YearMCK PortfolioMCK Income/yrRMD PortfolioRMD Income/yrGap
1$10,764$63.56$10,844$143.91$80.00RMD
2$11,624$106.59$11,801$198.21$177.00RMD
3$12,617$179.33$12,901$273.96$284.00RMD
4$13,803$303.26$14,185$380.39$382.00RMD
5$15,286$516.89$15,709$531.20$423.00RMD
6$17,248$891.81$17,556$747.16$308.00RMD
7← crossover$20,023$1,567.70$19,845$1,060.53+$178.00MCK
8$24,260$2,835.35$22,757$1,522.63+$1.5KMCK
9$31,310$5,352.05$26,567$2,217.64+$4.7KMCK
10$44,263$10,761.37$31,715$3,288.25+$12.5KMCK

MCK vs RMD: Complete Analysis 2026

MCKHealthcare

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

Full MCK Calculator →

RMDHealthcare

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Full RMD Calculator →
📬

Get this MCK vs RMD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MCK vs SCHDMCK vs JEPIMCK vs OMCK vs KOMCK vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.